| Mepha Pharma AG - Rivastigmin-Mepha Patch 13.3 mg/24 h, Transdermale Pflaster |
| 68795 | | 03 | | Rivastigmin-Mepha Patch 13.3 mg/24 h | | Transdermale Pflaster | | N06DA03 | | Rivastigmin | | 15.11.2022 | | |
|
| Composition |
| rivastigminum 19.2 mg, 2-ethylhexylis acrylatis et vinylis acetatis polymerisatum, polyisobutylenum, silica colloidalis anhydrica, paraffinum perliquidum, Trägermaterial: polyethylenum/aluminium polyesterum, polyesterum, ad praeparationem pro 12.8 cm², cum liberatione 13.3 mg/24h. |
| Packungsbestandteile |
| Transdermale Pflaster | | | | | Principe actif | Concentr. |
|---|
| Rivastigmine | 19.2 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Rivastigmine | 19.2 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| 2-ethylhexylis Acrylatis | | | | Ad Praeparationem | 12.8 cm | | | Cum Liberatione | 13.3mg / 24h | | | Paraffine Perliquide | | | | Polyesterum | | | | Polyethylenum/aluminium Polyesterum | | Trägermaterial | | Polyisobutylenum | | | | Silica Colloidalis Anhydrica | | | | Vinylis Acetatis Polymerisatum | | |
| |
|
|
